Sort   by:  
 Page size 
ProteomicsEffect of PTEN knockout on dabrafenib-trametinib treatment in A375 melanoma cells - replicate 1
Approximately 50% of melanomas harbor an activating BRAFV600E mutation. Standard of care involves a combination of inhibitors targeting mutant BRAF and MEK1/2, the substrate for BRAF in the MAPK pathway. PTEN loss of function mutations occur in 40% of BRAFV600E melanomas, resulting in increased PI3K...
ORGANISM(S): Homo sapiens (Human) 
2024-04-23 | PXD033866 | Pride
A375 Kinase inhibitor Braf Melanoma Mek Kinome 
ProteomicsEffect of oxygen tension on MMTV-PyMT tumor cell kinome
Solid tumors are characterized by significantly lower oxygen (O2) levels. Despite this fact, routine preclinical cancer studies are performed under ambient O2 conditions. We have developed an experimental approach that allows us to collect, process and evaluate cancer and non-cancer cells under phys...
ORGANISM(S): Mus musculus (Mouse) 
2024-05-08 | PXD046005 | Pride
Ambient Breast cancer Kinase inhibitor beads Physioxia Lapatinib 
ProteomicsKinome profiling of shControl and shFANCA THP1 cells treated with volasertib
The Fanconi anemia (FA) pathway is a network of proteins critical to the preservation of genomic integrity and the prevention of cancer. FA proteins safeguard the genome by regulating the cell cycle and facilitating error-free repair of DNA damage. Bi-allelic mutation of genes encoding FA pathway pr...
ORGANISM(S): Homo sapiens (Human) 
2024-11-21 | PXD048057 | Pride
Polo-like kinase 1 Kinase inhibitor Acute myeloid leukemia Fanconi anemia 
ProteomicsKinome profiling of shControl and shFANCA HL60 cells treated with volasertib
The Fanconi anemia (FA) pathway is a network of proteins critical to the preservation of genomic integrity and the prevention of cancer. FA proteins safeguard the genome by regulating the cell cycle and facilitating error-free repair of DNA damage. Bi-allelic mutation of genes encoding FA pathway pr...
ORGANISM(S): Homo sapiens (Human) 
2024-11-21 | PXD048014 | Pride
Polo-like kinase 1 Kinase inhibitor Acute myeloid leukemia Fanconi anemia 
ProteomicsKinome profiling of HRAS Q61K mutant SMS-CTR rhabdomyosarcoma cell line treated with tipifarnib
Hyperactive RAS signaling drives tumorigenesis in PAX 3/7::FOXO1 fusion-negative rhabdomyosarcoma (FN-RMS). Despite the frequency of these mutations, RAS pathway-directed therapies have been ineffective for RAS-driven RMS. Farnesyltransferase (FTase) inhibitors (FTIs), such as tipifarnib, inhibit HR...
ORGANISM(S): Homo sapiens (Human) 
2026-02-12 | PXD062989 | Pride
Mapk pathway Mek inhibition Ras Farnesyltransferase inhibitor Tumor 
ProteomicsDual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progressi...
ORGANISM(S): Mus musculus (Mouse) 
2024-11-20 | PXD035999 | Pride
Shp099 Therapeutics Patient-derived xenograft Kinase inhibitor Genetically engineered mouse model Hydroxychloroquine Neurofibromatosis type 1 Trametinib Kinome 
ProteomicsDual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progressi...
ORGANISM(S): Mus musculus (Mouse) 
2024-11-20 | PXD035998 | Pride
Shp099 Therapeutics Patient-derived xenograft Kinase inhibitor Genetically engineered mouse model Hydroxychloroquine Neurofibromatosis type 1 Trametinib Kinome 
ProteomicsPLK1 inhibition induces synthetic lethality in Fanconi anemia pathway-deficient acute myeloid leukemia
Overall survival of acute myeloid leukemia (AML) remains limited. Inhibitors of the master mitotic kinase PLK1 have emerged as promising therapeutics, demonstrating efficacy in an undefined subset of AML patients. However, the clinical success of PLK1 inhibitors remains hindered by a lack of predict...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-12-09 | MSV000096625 | MassIVE
UnknownGlobal hospital-based disease management of acute diverticulitis: a prospective, international cohort study.
Not available
S-EPMC12512976 | biostudies-literature
Sort   by:  
 Page size